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Abstract: This study was conducted to determine the concordance of results for a pair of structural isomers, 2-nitro-
propane (2-NP) and 1-nitropropane (1-NP), using the rat medium-term liver carcinogenesis bioassay (Ito test) and previ-
ously published long-term carcinogenicity tests. Male F344 rats were given a single intraperitoneal injection of DEN 
(200 mg/kg b.w.) to initiate hepatocarcinogenesis. After 2 weeks, they received per os 0, 0.8, 4 or 20 mg/kg/day of 2-NP 
or 1-NP six times a week and were subjected to two-thirds partial hepatectomy at week 3. Non-initiated groups receiving 
0 or 20 mg/kg/day were also included. The animals were sacrificed for quantitative analysis of GST-P-positive foci at 
week 8. With the highest dose of 2-NP, significantly increased numbers and areas of GST-P-positive foci were demon-
strated as compared with the respective control but were not noted with 1-NP. In the non-DEN-initiated groups, many 
small GST-P-positive foci of less than 0.2 mm in diameter were also induced in the rats treated with 2-NP at 20 mg/kg/
day but were lacking with 1-NP. These results strongly support that 2-NP is a complete hepatocarcinogen with a potent 
initiation activity, whereas 1-NP is not. (DOI: 10.1293/tox.24.207; J Toxicol Pathol 2011; 24: 207–213)
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Introduction
2-Nitropropane (2-NP) was once widely used as a 
chemical intermediate and as a solvent component of paints, 
inks and varnishes1,2. It has also been detected in cigarette 
smoke in significant quantities3. Results of in vivo long-term 
bioassays in rats given 2-NP via gavage or inhalation in fact 
showed the compound to be a potent liver carcinogen4,5, and 
the overall evaluation is category 2B in the IARC Mono-
graphs from positive animal data2. In contrast, 1-nitropro-
pane (1-NP), a structural isomer utilized as a propellant fuel, 
gasoline additive and in chemical syntheses1, was not found 
to be a hepatocarcinogen in a series of experiments5–7. Fur-
thermore, while 2-NP proved to be mutagenic in a variety 
of short-term mutagenesis assays, including the Ames/Sal-
monella8–10, in vitro sister chromatid exchange (SCE) and 
chromosome aberration11, V79/HGPRT forward mutation 
and in vitro and in vivo unscheduled DNA synthesis (UDS) 
assays12,13, positive data for 1-NP are limited to in vitro V79/
HGRPT cells12. Neither was found to be mutagenic in mi-
cronucleus tests with polychromatic erythrocytes14,15. 2-NP 
does not appear to resemble any of the known classes of 
chemical carcinogens. Regarding the mechanisms of its car-
cinogenicity, 2-NP causes oxidative DNA and RNA dam-
age in the rat liver resulting from intracellular generation 
of reactive forms of oxygen and/or 8-hydroxyguanine and 
8-hydroxy-2’-deoxyguanosine16,17. Sodum et al. proposed 
from in vivo and in vitro experimental evidence that activa-
tion to an aminating species by rat liver aryl sulfotransfer-
ase is involved18,19. In addition, it was suggested that 2-NP 
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and its nitronate, an NO species, may mediate or contribute 
to genotoxicity20. A positive association between increased 
cell proliferation as assessed by incorporation of bromo-
deoxyuridine and hepatocarcinogenesis has been reported 
for 2-NP, but not 1-NP21. Preneoplastic lesions, γ-glutamyl 
transpeptidase (γ-GT) and glutathione S-transferase placen-
tal form (GST-P)-positive foci, were also produced in Wis-
tar rats injected intraperitoneally with 2-NP in the initiation 
stage22.
The structures of 1-NP and 2-NP differ by only a little, 
but they differ greatly in their carcinogenic activity in the 
liver. In the present experiment, we investigated whether the 
two isomers promote development of GST-P-positive foci, 
as end-point lesions, in a medium-term liver carcinogenesis 
bioassay23–25  to  determine  their  sensitivity  and  specific-
ity for distinguishing carcinogenic from non-carcinogenic 
chemicals25–31.
Materials and Methods
All experimental procedures were performed in accor-
dance with the in-house guidelines for the Care and Use of 
Laboratory Animals at DIMS Institute of Medical Science, 
Inc.
Test chemicals and initiator
2-nitropropane (2-NP) and 1-nitropropane (1-NP) were 
purchased from Aldrich Chemical Co., Milwaukee, WI, 
USA. Diethylnitrosamine (DEN) was purchased from To-
kyo Chemical Industry Co., Ltd., Tokyo, Japan and used as 
an initiator of liver carcinogenesis. Regarding the reason for 
the determined dose level of test chemicals, a daily oral dose 
of 20 mg/kg/day, which did not show hepatocellular injury 
and increase in cell proliferation in a 2-week short-term oral 
administration study of 2-NP21, was selected as the highest 
dose level in the present experiment. The lower levels were 
set at 4 and 0.8 mg/kg/day using a proportional factor of 5. 
The 1-NP dosage was the same as that for 2-NP to enable 
comparison.
Animals and maintenance
Male F344/DuCrj and F344/DuCrlCrlj rats, 5 weeks 
of age, were purchased from Charles River Laboratories 
Japan, Inc., Atsugi, Japan, and housed two or three to a 
polycarbonate cage with hardwood Beta chips (Northeast-
ern Products Co., Warrensburg, NY, USA) for bedding. The 
animals were supplied with food (Oriental MF, Oriental 
Yeast Co., Ltd., Tokyo, Japan) and tap water ad libitum, and 
the room temperature and relative humidity were controlled 
at 20–24 °C and 48–59%, respectively. Fluorescent lighting 
provided a 12-hr light/dark cycle. After a one-week quaran-
tine and acclimation period, during which body weight and 
health conditions were monitored, a total of 159 rats were 
used for two experiments at 6 weeks of age.
Experimental procedure and autopsy
In experiment 1, from a total 78 male F344/DuCrj rats, 
72 were allocated to 6 groups (15 rats each for groups 1 to 
4 and 6 rats each for groups 5 and 6) using a computerized 
stratified body weight technique. At 6 weeks of age, animals 
of groups 1 to 4 were initially given a single intraperito-
neal injection of DEN at a dose of 200 mg/kg b.w. dissolved 
in saline to initiate hepatocarcinogenesis32. Rats of groups 
5 and 6 received the saline vehicle instead. After 2 weeks, 
animals of groups 1 to 4 were given 0, 0.8, 4 or 20 mg/kg/
day per os of 2-NP, dissolved in corn oil, while non-DEN-
initiated groups 5 and 6 received 0 and 20 mg/kg/day of 
2-NP, respectively, for 6 weeks 6 times per week, with no 
dosing on Sunday. All animals were subjected to two-thirds 
partial hepatectomy (PH) at the end of week 3. The animals 
were observed daily for abnormalities, and body weights 
and food consumption were measured once a week.
In experiment 2, from a total 97 male F344/DuCrlCrlj 
rats, 87 were allocated to 7 groups (15 rats each for groups 
1 to 5 and 6 rats each for groups 6 and 7) using the same 
technique as detailed above. At 6 weeks of age, animals of 
groups 1 to 4 were used under the same experimental re-
gime, given 0, 0.8, 4 or 20 mg/kg/day of 1-NP dissolved in 
corn oil in place of 2-NP as the test compound, with an addi-
tional group of 15 rats receiving 2-NP at 20 mg/kg/day as a 
positive control. Non-DEN-initiated groups 6 and 7 received 
0 and 20 mg/kg/day of 1-NP, respectively. Two-thirds PH 
was also conducted at the end of week 3. The animals were 
observed daily for abnormalities, and body weights and 
food consumption were measured once a week. Surviving 
rats in each group were sacrificed at the end of experimental 
week 8. At sacrifice in both experiments, livers were im-
mediately excised and weighed to allow calculation of the 
liver-to-body weight ratio. A total of three 4 to 5 mm-thick 
slices from the cranial and caudal parts of the right lateral 
lobes, and the cranial part of the caudate lobe were cut with 
a razor blade and fixed in 10% buffered formalin for immu-
nohistochemical demonstration of glutathione S-transferase 
placental form (GST-P)-positive foci.
Immunohistochemical staining and measurement of 
GST-P-positive foci
The avidin-biotin-peroxidase complex (ABC) method 
was used to stain GST-P-positive foci. After deparaffiniza-
tion, liver sections were treated sequentially with normal 
goat serum, anti-rabbit GST-P antibody (Medical Biological 
Laboratories Co., Ltd., Nagoya, Japan; 1:2000) and biotin-
labeled goat anti-rabbit IgG (1:200) for 1 hr using an Elite 
ABC kit (Vector Laboratories, Burlingame, CA, USA). The 
sites of peroxidase binding were visualized with diamino-
benzidine tetrahydrochloride, and the nuclei were counter-
stained with hematoxylin. All GST-P-positive foci larger 
than 0.2 mm in diameter (the lowest limit for reliable evalu-
ation) were measured using a color video image processor 
(IPAP-WIN, Sumika Technos, Osaka, Japan), and the num-
bers and areas of foci/square centimeter (cm2) of liver sec-
tions were calculated.Doi, Tamano, Kawabe et al. 209
Small GST-P-positive foci of less than 0.2 mm in di-
ameter were found in the non-DEN-initiated rats. The sizes 
of these GST-P-positive foci were evaluated under a micro-
scope as follows: single cell, 2 to 4 cells, 5 to 10 cells or 11 
cells or more.
Statistical analysis
The  significance  of  differences  for  each  parameter 
(excluding general conditions and food consumption) was 
analyzed and evaluated at P<0.05 or 0.01. Statistical com-
parisons between group 1 and groups 2 to 4 for numerical 
data were conducted using the Bartlett’s test (evaluated at 
P<0.05). If homogeneous, the data were analyzed with the 
Dunnett’s multiple comparison test (one sided), and if not, 
they were analyzed with the Steel’s test (one sided)33,34. Sta-
tistical comparisons between groups 5 and 6 (experiment 
1) and between groups 1 and 5 and groups 6 and 7 (experi-
ment 2) for numerical data were conducted using the F test. 
If homogeneous, the data were analyzed with the Student’s 
t-test (two sided), and if not, they were analyzed with the 
Welch test.
Results
Neither mortality nor clinical changes related to the 
test compound treatment were apparent in any of the groups. 
Average body weight values for animals exposed to DEN 
were lower than those of rats without DEN initiation at week 
1 and thereafter continued to be depressed until termination 
at week 8. Throughout the period of test material treatment 
(weeks 3 to 8), the mean body weight values of rats given 
2-NP or 1-NP were comparable to the corresponding control 
values, although the values for rats treated with 20 mg/kg of 
1-NP with DEN initiation were significantly lower than the 
control values in experiment 2 (data not shown). Food con-
sumption by 2-NP- or 1-NP-treated animals was comparable 
to the corresponding control values throughout the experi-
ment (data not shown).
Final average body weights for rats given 20 mg/kg/day 
of 1-NP with DEN initiation were significantly lower than 
those of control group 1. Those of the other groups were 
comparable to control values (Tables 1 and 2). Absolute and 
relative liver weights of rats treated with 0.8 and 20 mg/kg/
day of 2-NP with DEN initiation were significantly higher 
than those of control group 1, and those of the rats treated 
with 20 mg/kg/day of 2-NP without DEN initiation were 
significantly higher as compared with control group 5 (Ta-
ble 1). The relative liver weights of rats treated with 20 mg/
kg/day of 1-NP with DEN initiation were also significantly 
higher than those of control group 1 (Table 2). The abso-
lute and relative liver weights of rats treated with 20 mg/kg/
day of 2-NP with DEN initiation, reference group 5, were 
significantly higher than those of control group 1 (Table 2). 
As macroscopic findings, pale color and several whitish/yel-
lowish points in the liver were observed in rats treated with 
20 mg/kg/day of 2-NP with DEN initiation (data not shown).
The numbers and areas of GST-P-positive foci for rats 
treated 20 mg/kg/day of  2-NP with DEN initiation were 
Table 1.  Final Body and Liver Weights of Male F344/DuCrj Rats Initiated with or without DEN Followed by 2-Nitropropane (2-NP) 
Administration and Partial Hepatectomy in Experiment 1
Group
Treatment Effective 
No. of rats
Final body weight (g)a
Liver weight a
DEN 2-NP (mg/kg/day) Absolute (g) Relative (g/100 g body weight)
1 + 0 15 240.5 ± 9.8 5.63 ± 0.35 2.34 ± 0.07
2 + 0.8 13 244.5 ± 13.0 5.93 ± 0.36* 2.42 ± 0.07**
3 + 4.0 15 237.1 ± 12.2 5.61 ± 0.43 2.36 ± 0.08
4 + 20.0 15 239.7 ± 8.5 6.31 ± 0.36** 2.63 ± 0.10**
5 – 0 6 243.0 ± 14.7 5.85 ± 0.31 2.41 ± 0.10
6 – 20.0 6 253.0 ± 11.0 6.68 ± 0.34## 2.64 ± 0.07##
*, ** Significantly different from the control group (group 1) at P<0.05 and 0.01, respectively. ## Significantly different from the control 
group (group 5) at P<0.01. a Values indicate the mean ± SD.
Table 2.  Final Body and Liver Weights of Male F344/DuCrlCrlj Rats Initiated with or without DEN Followed by 1-Nitropropane (1-
NP) Administration and Partial Hepatectomy in Experiment 2
Group
Treatment Effective 
No. of rats
Final body weight (g)b
Liver weight b
DEN 1-NP (mg/kg/day) Absolute (g) Relative (g/100 g body weight)
1 + 0 14 233.2 ± 12.9 5.58 ± 0.44 2.39 ± 0.09
2 + 0.8 14 234.5 ± 13.3 5.61 ± 0.43 2.39 ± 0.07
3 + 4.0 15     233.5 ± 8.8 5.68 ± 0.32 2.43 ± 0.11
4 + 20.0 14 221.2 ± 9.0** 5.55 ± 0.34 2.51 ± 0.14**
5a + 20.0 15 231.7 ± 12.6 6.31 ± 0.48** 2.72 ± 0.10**
6 – 0 6 245.2 ± 16.5 5.91 ± 0.50 2.41 ± 0.13
7 – 20.0 6 243.0 ± 13.8 6.15 ± 0.61 2.52 ± 0.12
** Significantly different from the control group (group 1) at P<0.01. a 2-Nitropropane was used as a positive substance. b Values 
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significantly higher than those of control group 1 in experi-
ment 1 (Table 3). On the other hand, 1-NP did not promote 
the development of GST-P-positive foci in experiment 2, al-
though a slight significant increase in number was evident 
in rats given 0.8 mg/kg/day of 1-NP with DEN initiation, 
with no dose dependence (Table 4). In the non-DEN-initi-
ated groups, a number of small GST-P-positive foci of less 
than 0.2 mm in diameter developed in the rats given 20 mg/
kg/day of 2-NP, and this was significantly higher than the 
control value (group 5) in experiment 1 (Table 5). However, 
no such findings were evident for 1-NP (group 6) in experi-
ment 2 (Table 6).
Table 3.  Numbers and Areas of GST-P-positive Foci (0.2 mm or More in Diameter) in Male F344/DuCrj 
Rats Initiated with or without DEN Followed by 2-Nitropropane (2-NP) Administration and 
Partial Hepatectomy in Experiment 1
Group
Treatment Effective 
No. of rats
GST-P-positive foci a
DEN 2-NP (mg/kg/day) Number (No./cm2) Area (mm2/cm2)
1 + 0 15 3.39 ± 2.20 0.25 ± 0.17
2 + 0.8 13 3.50 ± 2.44 0.24 ± 0.18
3 + 4.0 15 4.60 ± 1.94 0.33 ± 0.18
4 + 20.0 15 10.83 ± 3.36** 0.88 ± 0.31**
5 - 0 6 0.00 ± 0.00 0.00 ± 0.00
6 - 20.0 6 0.00 ± 0.00 0.00 ± 0.00
** Significantly different from the control group (group 1) at P<0.01. a Values indicate the mean±SD.
Table 4.  Numbers and Areas of GST-P-positive Foci (0.2 mm or More in Diameter) in Male F344/Du-
CrlCrlj Rats Initiated with or without DEN Followed by 1-Nitropropane (1-NP) Administration 
and Partial Hepatectomy in Experiment 2
Group
Treatment Effective 
No. of rats
GST-P-positive foci b
DEN 1-NP (mg/kg/day) Number (No./cm2) Area (mm2/cm2)
1 + 0 14 3.64 ± 1.01 0.31 ± 0.12
2 + 0.8 14 4.95 ± 1.99* 0.43 ± 0.26
3 + 4.0 15 3.91 ± 1.78 0.33 ± 0.18
4 + 20.0 14 4.38 ± 1.46 0.32 ± 0.11
5a + 20.0  15 11.32 ± 1.54** 0.97 ± 0.17**
6 - 0 6 0.00 ± 0.00 0.00 ± 0.00
7 - 20.0 6 0.00 ± 0.00 0.00 ± 0.00
*, ** Significantly different from the control group (group 1) at P<0.05 and 0.01, respectively. a 2-nitropro-
pane was used as a positive substance. b Values indicate the mean ± SD.
Table 5.  Quantitative Analysis of GST-P-positive Foci of Less than 0.2 mm in Diameter in Male F344/DuCrj Rats Initiated without DEN 
Followed by 2-Nitropropane (2-NP) Administration and Partial Hepatectomy in Experiment 1
Group
Treatment Effective 
No. of rats
Size distribution of GST-P-positive foci (No./cm2)a
DEN 2-NP (mg/kg/day) Single cell 2-4 Cells 5-10 Cells >11 Cells Totalb
5 ‒ 0 6 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.07 ± 0.16 0.07 ± 0.16
6 ‒ 20.0 6 2.80 ± 1.17** 4.76 ± 1.67** 3.09 ± 1.11** 0.63 ± 0.66* 8.48 ± 2.45**
*, ** Significantly different from the control group (group 5) at P<0.05 and 0.01, respectively. a Values indicate the mean ± SD. b Single 
GST-P-positive cells were excluded.
Table 6.  Quantitative Analysis of GST-P-positive Foci of Less than 0.2 mm in Diameter in Male F344/DuCrlCrlj Rats Initiated without 
DEN Followed by 1-Nitropropane (1-NP) Administration and Partial Hepatectomy in Experiment 2
Group
Treatment Effective  
No. of rats
Size distribution of GST-P-positive foci (No./cm2)a
DEN 1-NP (mg/kg/day) Single cell 2-4 Cells 5-10 Cells >11 Cells Totalb
6 ‒ 0 6 0.42 ± 0.37 0.07 ± 0.17 0.00 ± 0.00 0.00 ± 0.00 0.07 ± 0.17
7 ‒ 20.0 6 0.00 ± 0.00* 0.00 ± 0.00 0.07 ± 0.17 0.13 ± 0.20 0.20 ± 0.22
* Significantly different from the control group (group 6) at P<0.05. a Values indicate the mean ± SD. b Single GST-P-positive cells were 
excluded.Doi, Tamano, Kawabe et al. 211
Discussion
In the present investigation, the liver carcinogen 2-NP 
gave an unequivocally positive result in the in vivo medium-
term liver carcinogenesis bioassay, whereas 1-NP proved 
negative. Preneoplastic GST-P-positive foci was significant-
ly increased in the rats treated with 20 mg/kg/day of 2-NP 
with DEN initiation, but not 4 mg/kg/day of 2-NP or less 
(experiment 1), pointing to a dose threshold.
Most importantly, the results of the present carcino-
genesis bioassay were in accordance with the earlier finding 
that 2-NP is a potent rat liver carcinogen according to long-
term in vivo carcinogenicity tests with exposure by inhala-
tion (207 ppm) and per os (1 mmol/kg)4,5. No toxicological 
effects were observed in the rats given 1-NP of 20 mg/kg/
day except for the retardation of body weight. In contrast, 
increased liver weights were shown in the rats treated with 
2-NP of 20 mg/kg/day. Moreover, the number of small GST-
P-positive foci of less than 0.2 mm in diameter was signif-
icantly increased in the rats treated with 2-NP of 20 mg/
kg/day without DEN initiation plus PH but not in the rats 
treated with 1-NP. Therefore, it was suggested that 2-NP 
is a complete hepatocarcinogen, displaying both promot-
ing and initiating activities, in accordance with the results 
of a previous initiation bioassay focusing on induction of 
γ-GT-positive and GST-P-positive foci22. 2-NP, categorized 
as complete hepatocarcinogen, indicates increase of GST-
P-positive foci in both with and without DEN initiation 
treatment. 1-NP, as non-hepatocarcinogen, demonstrates no 
increase in GST-P-positive foci even after DEN initiation 
treatment.
With regard to the mechanism of mutagenicity, oxida-
tive damage to DNA and RNA was demonstrated for 2-NP, 
eliciting 8-hydroxyguanine and 8-hydroxy-2’-deoxyguano-
sine, products of hydroxyl radical attack that can cause 
DNA misreplication16,17. It is therefore very likely that a 
modification of DNA and/or RNA and hepatocellular pro-
liferation are involved in 2-NP carcinogenicity21. Another 
mechanism might be related to NH2
+, an aminating species, 
activated by aryl sulfotransferase, resulting in 8-aminogua-
nine products. In contrast, the isomer 1-NP appears not to be 
a substrate for aryl sulfotransferase18,19.
With another pair of structural isomers, 2,4-diamino-
toluene (2,4-DAT), but apparently not 2,6-diaminotoluene 
(2,6-DAT), proved to be hepatocarcinogenic35,36, although 
both were found to be genotoxic in the Ames/Salmonella 
assay, and the metabolism of both compounds is mediated 
in a similar manner37,38. Cunningham and Matthews have 
documented that the difference may depend upon induc-
tion of cell proliferation. In the toxicological profile of the 
liver, clinical chemistry does not appear to differ between 
2-NP and 1-NP21. However, increased cell proliferation was 
limited to the case with 2-NP, which proved to be carcino-
genic39. Hepatocellular proliferation was similarly displayed 
at extremely high levels in the rats treated with 2,4-DAT but 
was lacking with 2,6-DAT40. Cell proliferation, therefore, 
may be an essential correlate of carcinogenicity with both 
2-NP and 2,4-DAT liver carcinogens. Thus, after initiated 
cells are generated in the liver in the two-step theory model 
with partial hepatectomy, whereby pluripotential cells in the 
intermediate cell population undergo replication, the prob-
ability that another genetic alteration mistake can occur that 
leads to the development of cancer is augmented. With re-
peated cell divisions, initiated populations colonally expand 
to produce identifiable specific intermediate lesions such as 
GST-P-positive foci, which can be quickly and easily as-
sessed as evidence for carcinogenic or non-carcinogenic 
potential41,42.
In conclusion, the present medium-term liver bioas-
say clearly demonstrated 2-NP, but not 1-NP, to be a he-
patocarcinogen, in accordance with published results for in 
vivo long-term carcinogenesis. Moreover, it was concluded 
that 2-NP was a complete hepatocarcinogen with genotoxic 
activity, showing that it displayed GST-P-positive activity 
both with and without DEN initiation treatment in this bio-
assay system.
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